BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 2021;500:1-10. [PMID: 33359211 DOI: 10.1016/j.canlet.2020.12.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 68] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Ge J, Yang N, Yang Y, Yu H, Yang X, Wang Y, Wang T, Cheng S, Wang Y, Han Z, Teng Y, Zou J, Yang H, Cheng L. The combination of eddy thermal effect of biodegradable magnesium with immune checkpoint blockade shows enhanced efficacy against osteosarcoma. Bioactive Materials 2023;25:73-85. [DOI: 10.1016/j.bioactmat.2023.01.008] [Reference Citation Analysis]
2 Liu J, Xu Y, Xu T, Liu Y, Liu J, Chai J, Yang Y, Hu P, Li M, Jia Q, Zhang C. MUC1 promotes cancer stemness and predicts poor prognosis in osteosarcoma. Pathol Res Pract 2023;242:154329. [PMID: 36680928 DOI: 10.1016/j.prp.2023.154329] [Reference Citation Analysis]
3 Fang L, Li Z, Yu B, Zhou L. FGF23 promotes proliferation, migration and invasion by regulating miR-340-5p in osteosarcoma. J Orthop Surg Res 2023;18:12. [PMID: 36604721 DOI: 10.1186/s13018-022-03483-w] [Reference Citation Analysis]
4 Capobianco E, McGaughey V, Seraphin G, Heckel J, Rieger S, Lisse TS. Vitamin D inhibits osteosarcoma by reprogramming nonsense-mediated RNA decay and SNAI2-mediated epithelial-to-mesenchymal transition. bioRxiv 2023:2023. [PMID: 36711643 DOI: 10.1101/2023.01.04.522778] [Reference Citation Analysis]
5 Wei Z, Zheng D, Pi W, Qiu Y, Xia K, Guo W. Isoquercitrin restrains the proliferation and promotes apoptosis of human osteosarcoma cells by inhibiting the Wnt/β-catenin pathway. J Bone Oncol 2023;38:100468. [PMID: 36685044 DOI: 10.1016/j.jbo.2023.100468] [Reference Citation Analysis]
6 Xu K, Fei W, Huo Z, Wang S, Li Y, Yang G, Hong Y. PDCD10 promotes proliferation, migration, and invasion of osteosarcoma by inhibiting apoptosis and activating EMT pathway. Cancer Med 2023;12:1673-84. [PMID: 35848121 DOI: 10.1002/cam4.5025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang Y, Wei J, Kong L, Song M, Zhang Y, Xiao X, Cao H, Jin Y. Network pharmacology, molecular docking and bioinformatics reveal the mechanism of Tripterygii Wilfordii against Osteosarcoma. Medicine (Baltimore) 2022;101:e32389. [PMID: 36595977 DOI: 10.1097/MD.0000000000032389] [Reference Citation Analysis]
8 Zhu P, Li T, Li Q, Gu Y, Shu Y, Hu K, Chen L, Peng X, Peng J, Hao L. Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma. Biomolecules 2022;12. [PMID: 36551309 DOI: 10.3390/biom12121882] [Reference Citation Analysis]
9 Chen C, Shi Q, Xu J, Ren T, Huang Y, Guo W. Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma. Cell Death Discov 2022;8:488. [PMID: 36509754 DOI: 10.1038/s41420-022-01252-6] [Reference Citation Analysis]
10 Wang X, Xie C, Lin L. Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma. J Bone Oncol 2023;38:100463. [PMID: 36569351 DOI: 10.1016/j.jbo.2022.100463] [Reference Citation Analysis]
11 Rothzerg E, Feng W, Song D, Li H, Wei Q, Fox A, Wood D, Xu J, Liu Y. Single-Cell Transcriptome Analysis Reveals Paraspeckles Expression in Osteosarcoma Tissues. Cancer Inform 2022;21:11769351221140101. [PMID: 36507075 DOI: 10.1177/11769351221140101] [Reference Citation Analysis]
12 Zhang L, Wu S, Huang J, Shi Y, Yin Y, Cao X. A mitochondria-related signature for predicting immune microenvironment and therapeutic response in osteosarcoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1085065] [Reference Citation Analysis]
13 Li L, Zhou X, Zhang W, Zhao R. Identification of Key Genes and miRNAs Affecting Osteosarcoma Based on Bioinformatics. Disease Markers 2022;2022:1-9. [DOI: 10.1155/2022/1015593] [Reference Citation Analysis]
14 Xia Y, Wang D, Piao Y, Chen M, Wang D, Jiang Z, Liu B. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1025532] [Reference Citation Analysis]
15 Zhang Y, Li Z, Wei J, Kong L, Song M, Zhang Y, Xiao X, Cao H, Jin Y. Network pharmacology and molecular docking reveal the mechanism of Angelica dahurica against Osteosarcoma. Medicine 2022;101:e31055. [DOI: 10.1097/md.0000000000031055] [Reference Citation Analysis]
16 Jintao Wu, Zhijian Jin, Jianwei Lin, Yucheng Fu, Jun Wang, Yuhui Shen. Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma. Front Immunol 2022;13:992266. [PMID: 36405691 DOI: 10.3389/fimmu.2022.992266] [Reference Citation Analysis]
17 Chen W, Lin W, Yu N, Zhang L, Wu Z, Chen Y, Li Z, Gong F, Li N, Chen X, He X, Wu Y, Zeng X, Yueh Y, Xu R, Ji G. Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect. IJN 2022;Volume 17:5431-5446. [DOI: 10.2147/ijn.s379917] [Reference Citation Analysis]
18 Huang W, Xiao Y, Wang H, Chen G, Li K. Identification of risk model based on glycolysis-related genes in the metastasis of osteosarcoma. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1047433] [Reference Citation Analysis]
19 Rothzerg E, Xu J, Wood D. Identification of Differentially Expressed Intronic Transcripts in Osteosarcoma. Noncoding RNA 2022;8. [PMID: 36412907 DOI: 10.3390/ncrna8060073] [Reference Citation Analysis]
20 Wang J, Wu Z, Zheng M, Yu S, Zhang X, Xu X. CD146 is closely associated with the prognosis and molecular features of osteosarcoma: Guidance for personalized clinical treatment. Front Genet 2022;13:1025306. [DOI: 10.3389/fgene.2022.1025306] [Reference Citation Analysis]
21 Yue J, Chen ZS, Xu XX, Li S. Functions and therapeutic potentials of exosomes in osteosarcoma. Acta Mater Med 2022;1:552-62. [PMID: 36710945 DOI: 10.15212/amm-2022-0024] [Reference Citation Analysis]
22 Todosenko N, Yurova K, Khaziakhmatova O, Malashchenko V, Khlusov I, Litvinova L. Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells. Pharmaceutics 2022;14:2181. [DOI: 10.3390/pharmaceutics14102181] [Reference Citation Analysis]
23 Yang J, Fu Q, Jiang H, Li Y, Liu M. Progress of phototherapy for osteosarcoma and application prospect of blue light photobiomodulation therapy. Front Oncol 2022;12:1022973. [DOI: 10.3389/fonc.2022.1022973] [Reference Citation Analysis]
24 Liu B, Liu Z, Feng C, Li C, Zhang H, Li Z, Tu C, He S. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma. Front Endocrinol 2022;13:987942. [DOI: 10.3389/fendo.2022.987942] [Reference Citation Analysis]
25 Xu N, Wang X, Wang L, Song Y, Zheng X, Hu H. Comprehensive analysis of potential cellular communication networks in advanced osteosarcoma using single-cell RNA sequencing data. Front Genet 2022;13:1013737. [DOI: 10.3389/fgene.2022.1013737] [Reference Citation Analysis]
26 Wang Z, Fan G, Zhu H, Yu L, She D, Wei Y, Huang J, Li T, Zhan S, Zhou S, Zhu Y, Wang Y, Chen X, Zhao J, Zhou G. PLOD2 high expression associates with immune infiltration and facilitates cancer progression in osteosarcoma. Front Oncol 2022;12:980390. [DOI: 10.3389/fonc.2022.980390] [Reference Citation Analysis]
27 Li M, Song Q, Bai Y, Hua F, Wu T, Liu J. Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma. Front Pharmacol 2022;13:992431. [DOI: 10.3389/fphar.2022.992431] [Reference Citation Analysis]
28 Luo X, Wu H, Xiong M, Jiang L, Jiang Z, Gong M. Split-DNAzyme cooperating primer exchange reaction for sensitive miRNA detection. J Anal Sci Technol 2022;13. [DOI: 10.1186/s40543-022-00343-4] [Reference Citation Analysis]
29 Jiang H, Du H, Liu Y, Tian X, Xia J, Yang S. Identification of novel prognostic biomarkers for osteosarcoma: a bioinformatics analysis of differentially expressed genes in the mesenchymal stem cells from single-cell sequencing data set. Transl Cancer Res 2022;11:3841-52. [PMID: 36388032 DOI: 10.21037/tcr-22-2370] [Reference Citation Analysis]
30 Li D, Zhang C, Tai X, Xu D, Xu J, Sun P, Fan Q, Cheng Z, Zhang Y. 1064 nm activatable semiconducting polymer-based nanoplatform for NIR-II fluorescence/NIR-II photoacoustic imaging guided photothermal therapy of orthotopic osteosarcoma. Chemical Engineering Journal 2022;445:136836. [DOI: 10.1016/j.cej.2022.136836] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Gao X, Gao B, Li S. Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma. Front Immunol 2022;13:1002742. [DOI: 10.3389/fimmu.2022.1002742] [Reference Citation Analysis]
32 Chen Y, Cheng S, Zhao C, Qian Y. Metacarpal osteosarcoma with chest wall metastasis: A case report. Asian J Surg 2022:S1015-9584(22)01279-9. [PMID: 36163098 DOI: 10.1016/j.asjsur.2022.09.023] [Reference Citation Analysis]
33 Yang G, Jiang J, Yin R, Li Z, Li L, Gao F, Liu C, Zhan X. Two novel predictive biomarkers for osteosarcoma and glycolysis pathways: A profiling study on HS2ST1 and SDC3. Medicine (Baltimore) 2022;101:e30192. [PMID: 36086752 DOI: 10.1097/MD.0000000000030192] [Reference Citation Analysis]
34 Peng L, Fang H, Yang X, Zeng X. Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma. Front Chem 2022;10:847621. [DOI: 10.3389/fchem.2022.847621] [Reference Citation Analysis]
35 Li M, Bao Q, Zhang Z, Wang B, Liu Z, Wen J, Wan R, Shen Y, Zhang W. Exceptional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma with tumor site infection. J Immunother Cancer 2022;10:e004673. [DOI: 10.1136/jitc-2022-004673] [Reference Citation Analysis]
36 Hu X, Zhou X, Zhang J, Li L. Sphingolipid metabolism is associated with osteosarcoma metastasis and prognosis: Evidence from interaction analysis. Front Endocrinol 2022;13:983606. [DOI: 10.3389/fendo.2022.983606] [Reference Citation Analysis]
37 Tan J, Feng X, Wu H, Yang B, Shi M, Xie C, Su Z, Li L, Luo M, Zuo Z, Zhu S, Yang J, Lin L, Cui D. Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures. Journal of Immunology Research 2022;2022:1-25. [DOI: 10.1155/2022/6568278] [Reference Citation Analysis]
38 Wang S, Chen C, Wang J, Li C, Zhou J, Liu Y, Jiang Y, Zhu L, Li C, Gong W, Guo W, Tang X, Yao F, Wang K. Synergetic Chemo‐Piezodynamic Therapy of Osteosarcoma Enabled by Defect‐Driven Lead‐Free Piezoelectrics. Adv Funct Materials. [DOI: 10.1002/adfm.202208128] [Reference Citation Analysis]
39 Chen Q, Zhou X, Jin J, Feng J, Xu Z, Chen Y, Zhao H, Li Z, Pan J. A Novel Defined RAS-Related Gene Signature for Predicting the Prognosis and Characterization of Biological Function in Osteosarcoma. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/5939158] [Reference Citation Analysis]
40 Jing S, Ding F, Yuan Y, An J, He Q. Efficacy of Neoadjuvant Chemotherapy plus Limb-Sparing Surgery for Osteosarcoma and Its Impact on Long-Term Quality of Life. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-6. [DOI: 10.1155/2022/1693824] [Reference Citation Analysis]
41 Lin A, Liu S, Wei H. Nanozymes for biomedical applications in orthopaedics. Particuology 2022. [DOI: 10.1016/j.partic.2022.08.009] [Reference Citation Analysis]
42 Yao W, Li S, Liu R, Jiang M, Gao L, Lu Y, Liang X, Zhang H. Long non-coding RNA PVT1: A promising chemotherapy and radiotherapy sensitizer. Front Oncol 2022;12:959208. [DOI: 10.3389/fonc.2022.959208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Liu W, Hao Y, Tian X, Jiang J, Qiu Q. The Role of NR4A1 in the Pathophysiology of Osteosarcoma: A Comprehensive Bioinformatics Analysis of the Single-Cell RNA Sequencing Dataset. Front Oncol 2022;12:879288. [DOI: 10.3389/fonc.2022.879288] [Reference Citation Analysis]
44 Zheng B, Song K, Sun L, Gao Y, Qu Y, Ren C, Yan P, Chen W, Guo W, Zhou C, Yue B. Siglec-15-induced autophagy promotes invasion and metastasis of human osteosarcoma cells by activating the epithelial-mesenchymal transition and Beclin-1/ATG14 pathway. Cell Biosci 2022;12:109. [PMID: 35842729 DOI: 10.1186/s13578-022-00846-y] [Reference Citation Analysis]
45 Ko Y, Jeong YH, Lee JA. Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells. Cells 2022;11:2164. [DOI: 10.3390/cells11142164] [Reference Citation Analysis]
46 Wang Z, Wei Y, Zhu H, Yu L, Zhu J, Han Q, Liu Z, Huang J, Zhu Y, Fan G, Tang Q, Qian J, Chen X, Zhou G. LncRNA NDRG1 aggravates osteosarcoma progression and regulates the PI3K/AKT pathway by sponging miR-96-5p. BMC Cancer 2022;22:728. [PMID: 35787258 DOI: 10.1186/s12885-022-09833-5] [Reference Citation Analysis]
47 Zhou Y, Li G, Li H, Lai F, Duan P, Cheng M, Wang F. Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma. Journal of Immunology Research 2022;2022:1-19. [DOI: 10.1155/2022/1377565] [Reference Citation Analysis]
48 Xie W, Chang W, Wang X, Liu F, Wang X, Yuan D, Zhang Y, Li T. Allicin Inhibits Osteosarcoma Growth by Promoting Oxidative Stress and Autophagy via the Inactivation of the lncRNA MALAT1-miR-376a-Wnt/β-Catenin Signaling Pathway. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/4857814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Liu J, Yao Q, Peng Y, Dong Z, Tang L, Su X, Liu L, Chen C, Ramalingam M, Cheng L. Identification of Small-Molecule Inhibitors for Osteosarcoma Targeted Therapy: Synchronizing In Silico, In Vitro, and In Vivo Analyses. Front Bioeng Biotechnol 2022;10:921107. [DOI: 10.3389/fbioe.2022.921107] [Reference Citation Analysis]
50 Peng Z, Li M, Wang Y, Yang H, Wei W, Liang M, Shi J, Liu R, Li R, Zhang Y, Liu J, Shi X, Wan R, Fu Y, Xie R, Wang Y. Self-Assembling Imageable Silk Hydrogels for the Focal Treatment of Osteosarcoma. Front Cell Dev Biol 2022;10:698282. [DOI: 10.3389/fcell.2022.698282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Cai D, Ma X, Guo H, Zhang H, Bian A, Yu H, Cheng W. Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration. J Orthop Surg Res 2022;17:305. [PMID: 35689249 DOI: 10.1186/s13018-022-03193-3] [Reference Citation Analysis]
52 Tuo B, Chen Z, Dang Q, Chen C, Zhang H, Hu S, Sun Z. Roles of exosomal circRNAs in tumour immunity and cancer progression. Cell Death Dis 2022;13:539. [PMID: 35676257 DOI: 10.1038/s41419-022-04949-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
53 Zhan H, Xiao J, Wang P, Mo F, Li K, Guo F, Yu X, Liu X, Zhang B, Dai M, Liu H, Miwa S. Exosomal CTCF Confers Cisplatin Resistance in Osteosarcoma by Promoting Autophagy via the IGF2-AS/miR-579-3p/MSH6 Axis. Journal of Oncology 2022;2022:1-18. [DOI: 10.1155/2022/9390611] [Reference Citation Analysis]
54 Wu R, Dou X, Li H, Sun Z, Li H, Shen Y, Weng W, Min J. Identification of Cell Subpopulations and Interactive Signaling Pathways From a Single-Cell RNA Sequencing Dataset in Osteosarcoma: A Comprehensive Bioinformatics Analysis. Front Oncol 2022;12:853979. [PMID: 35515114 DOI: 10.3389/fonc.2022.853979] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Li J, Su L, Xiao X, Wu F, Du G, Guo X, Kong F, Yao J, Zhu H. Development and Validation of Novel Prognostic Models for Immune-Related Genes in Osteosarcoma. Front Mol Biosci 2022;9:828886. [DOI: 10.3389/fmolb.2022.828886] [Reference Citation Analysis]
56 Lu Y, Zhang J, Chen Y, Kang Y, Liao Z, He Y, Zhang C. Novel Immunotherapies for Osteosarcoma. Front Oncol 2022;12:830546. [DOI: 10.3389/fonc.2022.830546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
57 Dong C, Wang Z, Shen P, Chen Y, Wang J, Wang H. Epigallocatechin-3-gallate suppresses the growth of human osteosarcoma by inhibiting the Wnt/β-catenin signalling pathway. Bioengineered 2022;13:8490-502. [PMID: 35348430 DOI: 10.1080/21655979.2022.2051805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Hong-bin S, Wan-jun Y, Chen-hui D, Xiao-jie Y, Shen-song L, Peng Z. Identification of an Iron Metabolism-Related lncRNA Signature for Predicting Osteosarcoma Survival and Immune Landscape. Front Genet 2022;13:816460. [DOI: 10.3389/fgene.2022.816460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Chen X, Liu L, Liu P, Chen Y, Lin D, Yan H, Yan Q, Wang Y, Qiu Y, Fang B, Huang H, Qian J, Zhao Y, Du Z, Zhang Q, Li X, Zheng X, Liu Z. Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma. J Med Chem 2022. [PMID: 35239349 DOI: 10.1021/acs.jmedchem.1c01732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Chen C, Guo Y, Huang Q, wang B, Wang W, Niu J, Lou J, Xu J, Ren T, Huang Y, Guo W. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Zhang F, Peng L, Shi C, Li J, Pang F, Fu W, Pan X, Zhang J. Baicalein mediates the anti-tumor activity in Osteosarcoma through lncRNA-NEF driven Wnt/β-catenin signaling regulatory axis. Journal of Orthopaedic Translation 2022;33:132-41. [DOI: 10.1016/j.jot.2021.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Chen Z, Li L, Li Z, Wang X, Han M, Gao Z, Wang M, Hu G, Xie X, Du H, Xie Z, Zhang H. Identification of key serum biomarkers for the diagnosis and metastatic prediction of osteosarcoma by analysis of immune cell infiltration. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02500-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Lu J, Kang X, Wang Z, Zhao G, Jiang B. The activity level of follicular helper T cells in the peripheral blood of osteosarcoma patients is associated with poor prognosis. Bioengineered 2022;13:3751-9. [PMID: 35081874 DOI: 10.1080/21655979.2022.2031387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Yao Q, Li Z, Chen D. Review of LINC00707: A Novel LncRNA and Promising Biomarker for Human Diseases. Front Cell Dev Biol 2022;10:813963. [DOI: 10.3389/fcell.2022.813963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Wu F, Xu J, Jin M, Jiang X, Li J, Li X, Chen Z, Nie J, Meng Z, Wang G. Development and Verification of a Hypoxic Gene Signature for Predicting Prognosis, Immune Microenvironment, and Chemosensitivity for Osteosarcoma. Front Mol Biosci 2021;8:705148. [PMID: 35071320 DOI: 10.3389/fmolb.2021.705148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Yuan Y, Diao S, Ni X, Zhang D, Yi W, Jian C, Hu X, Li D, Yu A, Zhou W, Fan Q. Peptide-based semiconducting polymer nanoparticles for osteosarcoma-targeted NIR-II fluorescence/NIR-I photoacoustic dual-model imaging and photothermal/photodynamic therapies. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01249-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
67 Jiang ZY, Liu JB, Wang XF, Ma YS, Fu D. Current Status and Prospects of Clinical Treatment of Osteosarcoma. Technol Cancer Res Treat 2022;21:15330338221124696. [PMID: 36128851 DOI: 10.1177/15330338221124696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Yao Q, Li Y, Pei Y, Xie B. Long non-coding RNA taurine up regulated 1 promotes osteosarcoma cell proliferation and invasion through upregulating Ezrin expression as a competing endogenous RNA of micro RNA-377-3p. Bioengineered 2022;13:1767-78. [PMID: 35012433 DOI: 10.1080/21655979.2021.1995578] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
69 刘 磊. Mining and Identification of Osteosarcoma Related Hub Genes Based on Microarray Data. ACM 2022;12:7598-7607. [DOI: 10.12677/acm.2022.1281097] [Reference Citation Analysis]
70 Sheng G, Gao Y, Yang Y, Wu H. Osteosarcoma and Metastasis. Front Oncol 2021;11:780264. [PMID: 34956899 DOI: 10.3389/fonc.2021.780264] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
71 Liu Z, Wen J, Hu F, Wang J, Hu C, Zhang W. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma. Cancer Sci 2021. [PMID: 34927311 DOI: 10.1111/cas.15237] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Wang J, Yuan L, Xu X, Zhang Z, Ma Y, Hong L, Ma J. Rho-GEF Trio regulates osteosarcoma progression and osteogenic differentiation through Rac1 and RhoA. Cell Death Dis 2021;12:1148. [PMID: 34893584 DOI: 10.1038/s41419-021-04448-3] [Reference Citation Analysis]
73 Casanova JM, Almeida JS, Reith JD, Sousa LM, Fonseca R, Freitas-Tavares P, Santos-Rosa M, Rodrigues-Santos P. Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival. Cancers (Basel) 2021;13:6075. [PMID: 34885185 DOI: 10.3390/cancers13236075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
74 Xiao B, Liu L, Chen Z, Li A, Xia Y, Wang P, Xiang C, Zeng Y, Li H. A Novel Overall Survival Prediction Signature Based on Cancer Stem Cell-Related Genes in Osteosarcoma. Front Cell Dev Biol 2021;9:753414. [PMID: 34733853 DOI: 10.3389/fcell.2021.753414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Leite TC, Watters RJ, Weiss KR, Intini G. Avenues of research in dietary interventions to target tumor metabolism in osteosarcoma. J Transl Med 2021;19:450. [PMID: 34715874 DOI: 10.1186/s12967-021-03122-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Hu X, Deng K, Ye H, Sun Z, Huang W, Sun Y, Yan W. Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study. Cancers (Basel) 2021;13:5381. [PMID: 34771548 DOI: 10.3390/cancers13215381] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
77 Zheng D, Yang K, Chen X, Li Y, Chen Y. Analysis of Immune-Stromal Score-Based Gene Signature and Molecular Subtypes in Osteosarcoma: Implications for Prognosis and Tumor Immune Microenvironment. Front Genet 2021;12:699385. [PMID: 34630511 DOI: 10.3389/fgene.2021.699385] [Reference Citation Analysis]
78 Zeng ZL, Zhu Q, Zhao Z, Zu X, Liu J. Magic and mystery of microRNA-32. J Cell Mol Med 2021;25:8588-601. [PMID: 34405957 DOI: 10.1111/jcmm.16861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
79 Wang X, Wang L, Xu W, Wang X, Ke D, Lin J, Lin W, Bai X. Classification of Osteosarcoma Based on Immunogenomic Profiling. Front Cell Dev Biol 2021;9:696878. [PMID: 34336848 DOI: 10.3389/fcell.2021.696878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
80 Martinez T, Sarda S, Dupret-Bories A, Charvillat C, Projetti F, Drouet C. Toward a doxorubicin-loaded bioinspired bone cement for the localized treatment of osteosarcoma. Future Oncol 2021;17:3511-28. [PMID: 34213375 DOI: 10.2217/fon-2021-0128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Jiang Y, Sun M, Ouyang N, Tang Y, Miao P. Synergistic Chemo-thermal Therapy of Cancer by DNA-Templated Silver Nanoclusters and Polydopamine Nanoparticles. ACS Appl Mater Interfaces 2021;13:21653-60. [PMID: 33905235 DOI: 10.1021/acsami.1c04608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]